Galaxy Therapeutics Opens New Manufacturing Facility to Support Global Commercialization

Galaxy Therapeutics Opens New Manufacturing Facility to Support Global Commercialization News provided by Galaxy Therapeutics Jul 30, 2025, 07:06 ET Share this article Share to X Share this article Share to X MILPITAS, Calif. , July 30, 2025 /PRNewswire/ -- Galaxy Therapeutics, a privately held, clinical-stage medical device company focused on treating brain aneurysms, today announced the official opening of its new 9,200 square foot (855 m²) facility designed to support the company's transition toward commercial readiness and global distribution. The newly inaugurated facility includes two ISO Class 7 Controlled Environment Rooms (CERs) totaling 2,400 square feet (223 m²), with one room measuring 1,000 square feet (93 m²) and the other 1,400 square feet (130 m²). In addition, the site features 1,500 square feet (139 m²) of dedicated R&D and manufacturing space, as well as ground-level roll-up doors to streamline shipping and receiving logistics. This expansion positions Galaxy to scale production, accelerate time-to-market, and provide global support for patients and clinical partners. "This new facility reflects our readiness to scale and deliver excellence for every patient we serve," said Jim Twitchell , Chief Operating Officer of Galaxy Therapeutics. "This milestone brings us closer to making transformative care a global reality," added Dr. Sam Zaidat, President and CEO. About Galaxy Therapeutics Galaxy Therapeutics is a private, U.S.-based clinical-stage medical device company founded by four practicing neurointerventional physicians. The company has developed a novel implant technology for the treatment of brain aneurysms and holds multiple patents across the U.S., EU, China , and other key markets. Headquartered in Milpitas, California , Galaxy Therapeutics is advancing multiple clinical programs globally and is committed to delivering effective, evidence-based solutions to physicians and patients. For more information, visit www.galaxytherapeutics.com , follow the company on LinkedIn. Logo: https://mma.prnewswire.com/media/2698518/5436139/Galaxy_Therapeutics_Logo.jpg SOURCE Galaxy Therapeutics 21 % more press release views with Request a Demo × Modal title